Optimising the strategy of care in early rheumatoid arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 24, Issue 4, 2010, Pages 443-455

  Dale, James ^a   Porter, Duncan ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

biologic DMARDS; clinical remission; disease modifying anti rheumatic drugs; early rheumatoid arthritis; low disease activity; tight control; window of opportunity

Indexed keywords

ABATACEPT; ADALIMUMAB; AUTOANTIBODY; COLONY STIMULATING FACTOR 1; CXCL13 CHEMOKINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPITOPE; ETANERCEPT; HLA DR ANTIGEN; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 6; METHOTREXATE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; ONCOSTATIN M; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; STAT4 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ANTIBODY PRODUCTION; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CLINICAL DISEASE ACTIVITY INDEX; COLLAGEN DEGRADATION; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DOPPLER ECHOGRAPHY; DRUG MEGADOSE; DRUG RESPONSE; EARLY DIAGNOSIS; EARLY INTERVENTION; FOLLOW UP; GENETIC PREDISPOSITION; HUMAN; IMMUNE DYSREGULATION; INFLAMMATION; MONOTHERAPY; MUSCULOSKELETAL DIAGNOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT CARE; PATIENT CARE PLANNING; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING; SIMPLIFIED DISEASE ACTIVITY INDEX; SYNOVITIS; THERAPY DELAY; TREATMENT PLANNING; CONVALESCENCE; IMMUNOMODULATION; METHODOLOGY; PATHOPHYSIOLOGY; RHEUMATOLOGY; TIME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; RECOVERY OF FUNCTION; REMISSION INDUCTION; RHEUMATOLOGY; TIME FACTORS;

EID: 77956135631     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.11.009     Document Type: Review

References (90)

1. D. McGonagle, P. Conaghan, and P. O'Connor The relationship between synovitis and bone changes in early untreated arthritis Arthritis Rheum 42 1999 1706 1711
2. I. Van der Horst-Bruinsma, I. Speyer, and H. Visser Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care Br J Rheumatol 37 1998 1084 1088
3. K. Saag, G. Teng, and N. Patkar American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 2008 762 784
4. National Collaborating Centre for Chronic Conditions Rheumatoid arthritis: national clinical guideline for management and treatment in adults February 2009 Royal College of Physicians
5. K. Eberhardt, and E. Fex Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years Br J Rheumatol 37 1998 1324 1329
6. T. Mottonen, P. Hannonen, and M. Korpela Delay to institution of therapy and induction of remission using single drug or combination disease modifying antirheumatic drug therapy in early rheumatoid arthritis Arthritis Rheum 46 2002 894 898
7. A. Finckh, M.H. LLang, C.M. van Herckenrode, and P. Pablo Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis Arthritis Rheum 55 2006 864 872
8. D.L. Scott, C. Smith, and G. Kingsley Joint damage and disability in rheumatoid arthritis: an updated systematic review Clin Exp Rheumatol 21 Suppl. 31 2003 S20 S27
9. D.P. Symmons, M.A. Jones, D.L. Scott, and P. Prior Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well J Rheumatol 25 1998 1072 1077
10. C. Egsmose, B. Lund, and G. Borg Patients with early rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective, double blind, placebo controlled study J Rheumatol 22 1995 2208 2213
11. J.J. Anderson, G. Wells, A. Verhoeven, and D. Felson Factors predicting response to treatment in rheumatoid arthritis. The importance of disease duration Arthritis Rheum 43 2000 22 29
12. R. Munro, R. Hampson, and A. McEntegart Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study Ann Rheum Dis 57 1998 88 93
13. M. Green, H. Marzo-Ortega, and D. McGonagle Persistence of mild, early inflammatory arthritis. The importance of disease duration, rheumatoid factor and the shared epitope Arthritis Rheum 42 1999 2184 2188
14. V. Rantalaiho, M. Korpela, and P. Hannonen The good initial response to therapy with a combination of traditional disease modifying antirheumatic drugs is sustained over time Arthritis Rheum 60 2009 1222 1231
15. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977
16. P. Conaghan, P. O'Connor, and D. McGonagle Elucidation of the relationship between synovitis and bone damage. A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis Arthritis Rheum 48 2003 64 71
17. M.C. Wick, S. Lindblad, L. Klareskog, and R.F. van Vollenhoven Relations between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description Ann Rheum Dis 63 2004 848 852
18. C. Grigor, H. Capell, and A. Stirling Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial Lancet 364 2004 263 269
19. S.M.M. Verstappen, J.W.G. Jacobs, and M.J. van dr Veen Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open label strategy trial) Ann Rheum Dis 66 2007 1443 1449
20. Y.P.M. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, and C.F. Allaart Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study) Arthritis Rheum 52 2005 3381 3390
21. T. Mottonen, Hannonen, and M. Leirisalo-Repo Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial Lancet 353 1999 1568 1573
22. E.H.S. Choy, C. Smith, C.J. Dore, and D.L. Scott A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal Rheumatology 44 2005 1414 1421
23. M. Boers, A.C. Verhoeven, and H.M. Markusse Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis Lancet 350 1997 309 318
24. R. Williams, D. Walsh, and A. Hassel Early rheumatoid arthritis network (ERAN) audit of ARMA standards of access to rheumatology services for patients with early RA Rheumatology 45 Suppl. 1 2006 i56
25. K.E. Donahue, G. Gartlehner, and D.E. Jonas Systematic effectiveness and harms of disease-modifying medications for rheumatoid arthritis Ann Intern Med 148 2008 124 134
26. H.K. Choi, M.A. Hernan, and J.D. Seegar Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study Lancet 359 2002 1173 1177
27. D.R. Porter, H.A. Capell, and J. Hunter Combination therapy in rheumatoid arthritis - no benefit from of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold J Rheumatol 20 1993 645 649
28. J.R. O'Dell, R. Leff, and G. Paulsen Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulphasalazine or a combination of the three medications. Results of a two year, randomized, double-blind, placebo-controlled trial Arthritis Rheum 46 2002 1164 1170
29. P. Tugwell, T. Pincus, and D. Yocum Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis N Engl J Med 333 1995 137 141
30. C.M. Stein, T. Pincus, and D. Yocum Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open label extension study Arthritis Rheum 40 1997 1843 1851
31. J.M. Kremer, M.C. Genovese, and G.W. Cannon Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable dose methotrexate Ann Intern Med 137 2002 726 733
32. A.J. Lehman, J.M. Esdaile, and A.V. Klinchoff A 48 week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis. Results of the METGO Study Arthritis Rheum 52 2005 1360 1370
33. C.J. Haagsma, P.L.C.M. van Riel, A.J.L. de Jong, and L.B.A. Van de Putte Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial Br J Rheumatol 36 1997 1082 1088
34. M. Dougados, B. Combe, and A. Cantagrel Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components Ann Rheum Dis 58 1999 220 225
35. M. Korpela, L. Laasonen, and P. Hannonen Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs. Five year experience from the FIN-RACo Study Arthritis Rheum 50 2004 2072 2081
36. K. Puolakka, H. Kautiainen, and T. Mottonen Impact of initial aggressive drug treatment with a combination of work disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis. A five-year randomized follow-up trial Arthritis Rheum 50 2004 55 62
37. V. Rantalaiho, M. Korpela, and P. Hannonen The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time. The eleven-year results of the Finnish Rheumatoid Arthritis Combination Therapy Trial Arthritis Rheum 60 2009 1222 1231
38. M.L. Hetland, K. Stengaard-Pedersen, and P. Junker Combination with methotrexate, cyclosporine and intra-articular betamethasone compared with methotrexate and intra-articular betamethasone in early, active rheumatoid arthritis. An investigator-initiated, randomized, double-blind, parallel group, placebo-controlled study Arthritis Rheum 54 2006 1401 1409
39. M.L. Hetland, K. Stengaard-Pedersen, and P. Junker Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second year clinical and radiographic results from the CIMESTRA study Ann Rheum Dis 67 2008 815 822
40. A. Marchesoni, N. Battafarano, and M. Arreghini Radiographic progression in early rheumatoid arthritis: a 12 month randomized controlled study comparing the combination of cyclosporine and methotrexate with methotrexate alone Rheumatology 42 2003 1545 1549
41. R.B.M. Landewe, M. Boers, and A.C. Verhoeven COBRA Combination therapy in patients with early rheumatoid arthritis. Long-term structural benefits of a brief intervention Arthritis Rheum 46 2002 347 356
42. Y.P.M. Goekoop-Ruiterman, J.K. de vries-Bouwstra, and C.F. Allaart Comparison of treatment strategies in early rheumatoid arthritis. A randomized trial Ann Intern Med 146 2007 406 415
43. S.A. Saunders, H.A. Capell, and A. Stirling Triple therapy in early, active rheumatoid arthritis. A randomized, single blind, controlled trial comparing step-up and parallel treatment strategies Arthritis Rheum 58 2008 1310 1317
44. R. Luqmani, S. Hennell, and C. Estrach British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the management of rheumatoid arthritis (the first 2 years) Rheumatology 45 2007 1167 1169
45. E.W. St Clair, D.M. van der Heidje, and J.S. Smolen Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial Arthritis Rheum 50 2004 3432 3443
46. F.C. Breedveld, M.H. Weisman, and A.F. Kavanaugh The PREMIER Study. A multicenter, randomized double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalumimab alone in patients with early, aggressive rheumatoid arthritis who had not received methotrexate treatment Arthritis Rheum 54 2006 26 37
47. P. Emery, F. Breedveld, and S. Hall Comparison of methotrexate monotherapy with a combination of methotrexare and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial Lancet 372 2008 375 382
48. P. Prior, D.P.M. Symmons, and D.L. Scott Cause of death in rheumatoid arthritis Br J Rheumatol 23 1984 92 99
49. F. Wolfe, D.M. Mitchel, and J.T. Sibley The mortality of rheumatoid arthritis Arthritis Rheum 37 1994 481 494
50. K. Ikeda, S. Cox, and P. Emery Biological therapy in early arthritis - overtreatment or the way to go? Arthritis Res Ther 9 2007 211 217
51. T. Bongatz, A.J. Sutton, and M.J. Sweeting Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2006 2275 2285
52. W.G. Dixon, K. Watson, and M. Lunt Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumour necrosis factor therapy Arthritis Rheum 54 2006 2368 2376
53. W.G. Dixon, D.P.M. Symmons, and M. Lunt Serious infection following anti-tumour necrosis factor alpha therapy in patients with rheumatoid arthritis. Lessons from interpreting data from observational studies Arthritis Rheum 56 2007 2896 2904
54. R.S. Wallis, M.S. Broder, and J.Y. Wong Granulomatous infectious diseases associated with tumour necrosis factor antagonists Clin Infect Dis 38 2004 1261 1265
55. J.J. Gomez-Reino, L. Carmona, and V.R. Valverde Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors may predispose to significant increases in tuberculosis risk: a multicenter active-surveillance report Arthritis Rheum 48 2003 2122 2127
56. P. Geborek, A. Bladstrom, and C. Turesson Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas Ann Rheum Dis 64 2005 699 703
57. J. Askling, C.M. Fored, and L. Brandt Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists Ann Rheum Dis 64 2005 1421 1426
58. J. Askling, C.M. Fored, and E. Baecklund Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists Ann Rheum Dis 64 2005 1414 1420
59. M.A. Quinn, P.G. Conaghan, and P.J. O'Connor Very early treatment with infliximab in addition to methotrexate in early, poor prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Results from a twelve-month randomized, double-blind, placebo controlled trial Arthritis Rheum 52 2005 27 35
60. C. Sheehy, E. Murphy, T. Duffy, and M. Barry Remission induction with etanercept and methotrexate in very early rheumatoid arthritis with sustained remission after etanercept withdrawal Arthritis Rheum 58 Suppl. 2008 S918
61. A.E. Van der Bijl, Y.P.M. Goekoop-Ruiterman, and J.K. de Vries-Bouwstra Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis Arthritis Rheum 56 2007 2129 2134
62. W.F. Rigby, G. Ferracciolo, and M. Greenwald Rituximab improved physical function and quality of life in patients with early rheumatoid arthritis; results from a randomized active comparator placebo-controlled trial of rituximab in combination with methotrexate compared to methotrexate alone Ann Rheum Dis 68 Suppl. 3 2009 581
63. R. Westhovens, M. Robles, and A.C. Ximes Clinical efficacy and safety of abatacept in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors Ann Rheum Dis 2009 10.1136/ard.2008.101121
64. M.M.J. Nielen, D. van Schaardenburg, and H.W. Reesink Specific autoantibodies precede the symptoms of rheumatoid arthritis. A study of serial measurements in blood donors Arthritis Rheum 50 2004 380 386
65. H. El-Gabalawy The preclinical stages of RA: lessons from human studies and animal models Best Pract Res Clin Rheumatol 23 2009 49 58
66. L.B. Chibnik, L.A. Mandl, and K.H. Costenbader Continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis J Rheumatol 36 2009 706 711
67. A. Ioan-Facsinay, A. Willemze, and D.B. Robinson Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease Arthritis Rheum 58 2008 3000 3008
68. M.P.M. Van der Linden, D. van der Woude, and A. Ioan-Facsinay Value of anti-modified citrullinated vimentin and third generation anti-cyclic citrullinated peptide compared with second generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis Arthritis Rheum 60 2009 2232 2241
69. J. Van Aken, H. van Dongen, and S. le Cessie Comparison of long-term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study Ann Rheum Dis 65 2006 20 25
70. A.H.M. Van der Helm-van Mil, J. Detert, and S. le Cessie Validation of a prediction rule for disease outcome in patients with recent onset undifferentiated arthritis. Moving towards individualized treatment decisions Arthritis Rheum 58 2008 2241 2247
71. J. Narvaez, E. Sirvent, and J. Antonio Narvaez Usefulness of magnetic resonance imaging of the hand versus anti-cyclic citrullinated peptide antibody testing to confirm the diagnosis of clinically suspected early rheumatoid arthritis in the absence of rheumatoid factor and radiographic erosions Semin Arthritis Rheum 38 2008 101 109
72. I. Eshed, E. Feist, and C.E. Althoff Tenosynovitis of the flexor tendons of the hand detected by MRI: an early indicator of rheumatoid arthritis Rheumatology 48 2009 887 891
73. D. Khanna, M. Oh, and D.E. Furst Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort Arthritis Rheum 57 2007 440 447
74. A.K. Brown, M.A. Quinn, and Z. Karim Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission. Evidence from an imaging study may explain structural progression Arthritis Rheum 54 2006 3761 3773
75. A.K. Brown, P.G. Conaghan, and Z. Karim An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis Arthritis Rheum 58 2008 2958 2967
76. M. Szkudlarek, M. Court-Payen, and C. Strandberg Power Doppler ultrasonography for assessment of synovitis in the metacarpophalangeal joints of patients with rheumatoid arthritis: a comparison with dynamic magnetic resonance imaging Arthritis Rheum 44 2001 2018 2023
77. M. Walther, H. Harms, and V. Krenn Correlation of power Doppler sonography with vascularity of the synovial tissue of the knee joint in patients with osteoarthritis and rheumatoid arthritis Arthritis Rheum 44 2001 331 338
78. E. Naredo, I. Moller, and A. Cruz Power Doppler ultrasonographic monitoring of response to anti-tumour necrosis factor therapy in patients with rheumatoid arthritis Arthritis Rheum 58 2008 2248 2256
79. E. Naredo, P. Collodo, and A. Cruz Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression Arthritis Rheum 57 2007 116 124
80. A.K. Sheel, K.G.A. Hermann, and E. Kahler A novel ultrasonographic synovitis scoring system suitable for analysing finger joint inflammation in rheumatoid arthritis Arthritis Rheum 52 2005 733 743
81. S. Ohrndorf, H. Kellner, and J. Strunk Evaluation of a novel 7 joint sonographic score (US7) in daily rheumatologic practice - 6 months results of multi center project in Germany Arthritis Rheum 58 Suppl. 2008 S464
82. E. Naredo, M. Rodriguez, and C. Campos Validity, reproducibility and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis Arthritis Rheum 59 2008 515 522
83. P. Emery, I.B. McInnes, R. van Vollenhoven, and M.C. Kraan Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis Rheumatology 47 2008 392 398
84. M.J. Plant, A.L. Williams, and M.M. O'Sullivan Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis Arthritis Rheum 43 2000 1473 1477
85. L. Innala, H. Kokkonen, and C. Eriksson Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinate peptides J Rheumatol 35 2008 1002 1008
86. I. Rioja, F.J. Hughes, and C.H. Sharp Potential novel biomarkers of disease activity in rheumatoid arthritis patients. CXCL13, CCL23, transforming growth factor α, tumour necrosis factor receptor superfamily member 9 and macrophage colony-stimulating factor Arthritis Rheum 58 2008 2257 2267
87. H. Marotte, E. Gineyts, P. Miossec, and P.D. Delma Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis Ann Rheum Dis 68 2009 1197 1200
88. L.H.D. Van Tuyl, W.F. Lems, and A.E. Voskuyl Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot study Ann Rheum Dis 67 2008 1574 1577
89. M.C. Genovese, S. Cohen, and L. Moreland Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate Arthritis Rheum 50 2004 1412 1419
90. S.B. Cohen, R.K. Dore, and N.E. Lane Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis. A twelve-month, multicenter, randomized, double-blind, placebo controlled, phase II clinical trial Arthritis Rheum 58 2008 1299 -1309